← SynDRA
AZD-1480
SynDRA canonical compound SYN0024187 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | JAK2 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- JAK inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- JAK2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLK
- FLT3
- AURKA
- AURKB
- SYK
- STRADA
- STK4
- STK3
- FGFR1
- STK11
- PTK2
- STK10
- STAT5A
- STAT3
- RET
- PAK4
- NTRK1
- CDK3
- PTK2B
- FER
- CSNK2A2
- YES1
- PLK4
- TNK1
- TNK2
- PFKP
- PKN2
- NUAK2
- OLA1
- OPA1
- PAICS
- PAK2
- PLK1
- PAK6
- PKN3
- PASK
- PKMYT1
- PKN1
- PEBP1
- PIP4K2C
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLA-B
- HLAB
- IFNB1
- KSYK
- NSD2
- PARP1
- TP53
Cross-references
Synonyms
- AZD1480
- RET inhibitors
- AZD 1480
- UNII-KL2Z2TLF01
- (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
- KL2Z2TLF01
- CHEMBL1231124
- 5-Chloro-N2-[(1s)-1-(5-Fluoropyrimidin-2-Yl)ethyl]-N4-(5-Methyl-1h-Pyrazol-3-Yl)pyrimidine-2,4-Diamine
- 2,4-Pyrimidinediamine, 5-chloro-N2-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)-
- C14H14ClFN8
- 2xa4
- MLS006011153
- GTPL5933
- SCHEMBL3345019
- DTXSID50239469
- EX-A450
- AZD 1480 [WHO-DD]
- BCPP000361
- BCP02413
- AZD1480,AZD 1480
- BDBM50335201
- NSC756648
- NSC799344
- s2162
- ZINC58631551
- AKOS027322548
- AM85979
- BCP9000361
- CCG-268021
- DB12588
- NSC-756648
- NSC-799344
- NCGC00242486-01
- NCGC00242486-02
- NCGC00242486-05
- 2,4-Pyrimidinediamine,5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-
- 5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine
- AC-32807
Look up AZD-1480 in the interactive SynDRA portal →